Hayward, Calif.-based Biolog has garnered another grant from the National Institutes of Health for a new application — this time in the area of antimicrobial drug development — for its Phenotype Microarray cellular array technology.

The additional $450,000 of funding will augment the approximately $2 million in separate grants that Biolog has received in the past three months to support the development of the Phenotype Microarray for applications ranging from detecting bioterrorism agents to functional genomic studies on yeast, Saccharomyces cerevisae.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.